Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update
Second quarter total revenue of $166 million,Crysvita® revenue of $120 million and Dojolvi® revenue of $23 million
Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million
UX143 for osteogenesis imperfecta Phase 3 data from Orbit and Cosmic studies expected around the end of the year
GTX-102 for Angelman syndrome received Breakthrough Therapy Designation from FDA;Phase 3 Aspire study fully enrolled
NOVATO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter ended June 30, 2025.
"In the first half of the year, we delivered 20% revenue growth from our commercial therapies versus the prior year. We are continuing along our path to profitability in 2027, as we drive our top line growth and maintain our fiscal discipline," said Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx. "We are excited for the potential of UX143 in osteogenesis imperfecta to reduce fractures and meaningfully improve patients' bone health and for GTX-102 in Angelman syndrome to transform the lives of patients and their families affected by this neurodevelopment disease."
Second Quarter 2025 Selected Financial Data Tables and Financial Results
Revenues (dollars in thousands), (unaudited)
Three Months Ended June 30,
Six Months Ended June 30,
2025
2024
2025
2024
Crysvita
Product sales, Latin America and Türkiye
$
34,727
$
40,449
$
89,807
$
76,690
Royalty revenue – U.S. and Canada
79,083
67,045
119,936
107,447
Royalty revenue – Europe
6,596
6,176
13,528
12,118
Total Crysvita Revenue
120,406
113,670
223,271
196,255
Dojolvi
23,207
19,355
40,216
35,717
Evkeeza
14,573
7,856
25,604
11,131
Mepsevii
8,310
6,145
16,697
12,756
Total revenues
$
166,496
$
147,026
$
305,788
$
255,859
Total RevenuesUltragenyx reported $166 million in total revenue for the second quarter of 2025, which represents 13% growth compared to the same period in 2024. Second quarter 2025 Crysvita revenue was $120 million, which includes product sales of $35 million from Latin America and Türkiye. Dojolvi revenue in the second quarter 2025 was $23 million. Evkeeza revenue in the second quarter 2025 was $15 million as we continue to launch in the Ultragenyx territories outside of the United States.
Selected Financial Data (dollars in thousands, except per share amounts), (unaudited)
Three Months Ended June 30,
Six Months Ended June 30,
2025
2024
2025
2024
Total revenues
$
166,496
$
147,026
$
305,788
$
255,859
Operating expenses:
Cost of sales
23,002
21,280
51,664
38,813
Research and development
164,736
161,503
330,508
339,990
Selling, general and administrative
86,646
80,604